SAN DIEGO, Jan. 5 /PRNewswire/ -- Dura Pharmaceuticals, Inc. (Dura)
(Nasdaq: DURA) today announced that it has appointed F. Richard Nichol, Ph.D.
to its Board of Directors. Dr. Nichol replaces David S. Kabakoff, Ph.D., who
concurrently resigned from the board of directors, but continues to serve as
President of Dura Technologies. The addition of Dr. Nichol increases the
number of non-employee board members from six to seven of the eight members,
leaving Cam L. Garner, Chairman and Chief Executive Officer of Dura, the only
Dura executive on the board.
Most recently, Dr. Nichol retired as President, Chief Executive Officer
and Chairman of the Board of CoCensys, Inc., a biopharmaceutical company in
Irvine, California. Prior to his role at CoCensys, Dr. Nichol was founder and
owner of Nichol Clinical Technologies Corporation, a company specializing in
clinical research and clinical data management. Prior to that, he served for
20 years as President and Chief Executive Officer of IBRD-Rostrum Global,
Inc., a full service contract research organization he co-founded.
"Dr. Nichol brings over 30 years of clinical, pharmaceutical and
biotechnology experience to Dura," stated Mr. Garner, Dura's Chairman and CEO.
"Dick's tremendous clinical background and broad experience should benefit
Dura as we move to strengthen our pipeline through late-stage product
acquisitions and continue development of the Spiros(R) products."
Dura Pharmaceuticals, Inc. is a San Diego based developer and marketer of
prescription pharmaceutical products for the treatment of allergies, asthma,
pneumonia and related respiratory conditions. Dura has focused on the U.S.
respiratory market because of its size and growth opportunities through two
major strategies: (1) acquiring prescription pharmaceuticals, product
candidates and/or businesses developing or marketing such pharmaceuticals to
support its marketing presence in high-prescribing respiratory physicians'
offices and/or the hospital market, and (2) developing Spiros(R), a pulmonary
drug delivery system for both topical and systemic delivery of medications.
Except for the historical and factual information contained herein, the
matters discussed in this press release may contain forward-looking statements
which involve risks and uncertainties, including the timely initiation and
successful completion of the clinical trial programs for the Spiros products,
the ability to obtain adequate funding to complete the clinical trial programs
for the Spiros products, the timely FDA approval of the Spiros products, if at
all, dependence on third parties for manufacturing and development, the
competitiveness of the pharmaceutical industry, and other risks detailed from
time to time in Dura's filings with the Securities and Exchange Commission.
Actual results may differ materially from those projected. Any forward-
looking statements represent Dura's judgment as of the date of this release.
Dura disclaims, however, any intent or obligation to update these forward-
looking statements. Further information about Dura Pharmaceuticals, Inc. can
be found at http://www.durapharm.com.
News releases from Dura Pharmaceuticals are available at no charge on
Dura's web site at http://www.durapharm.com and through PR Newswire's On-Call fax
service by calling (800) 758-5804, extension 197051.
SOURCE Dura Pharmaceuticals, Inc.
 back to top
Related links:
http://www.durapharm.com
Company News On-Call:
http://www.prnewswire.com/comp/197051.html or fax,
800-758-5804, ext. 197051
CONTACT:
Michael T. Borer, Senior Vice President and
Chief Financial Officer of Dura Pharmaceuticals, Inc.,
858-457-2553
|
